Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by recurrent eczema with exacerbations and remissions. AD impairs patients' QOL and places a heavy burden on patients. Recently, dupilumab, an anti-IL-4Rα antibody, was approved for the treatment of patients with moderate-to-severe AD who are refractory to topical agents and/or conventional systemic therapy. Clinical trials of dupilumab for AD demonstrated high efficacy and tolerable safety profiles. Furthermore, real-world evidence of dupilumab for AD is accumulating. Most of these data show favorable effectiveness and safety profile; however, they also clarified issues, including conjunctivitis and facial redness. There are still a certain number of patients with significant failure. In this article, we review real-world evidence of dupilumab for AD, identify concerns specific to dupilumab, and discuss unmet needs and issues to be addressed in the future.
Keywords: AA, alopecia areata; AD, atopic dermatitis; CsA, cyclosporin A; EASI, Eczema Area and Severity Index; HSV, herpes simplex virus; IGA, Investigator’s Global Assessment; LDH, lactate dehydrogenase; TCS, topical corticosteroid; Th, T helper type; q2w, every other week; qw, weekly.
© 2021 The Authors.